Baseline Ang-2 Serum Levels as a Predictive Factor for Survival in NSCLC and SCLC

Figures

• 

  Figure 1. Ang-2 serum levels of healthy controls compared with the Ang-2 serum levels of patients with lung cancer.

• 

  Figure 2. Kaplan–Meier curve for overall survival grouped by baseline serum Ang-2 levels. (A) Overall survival for stage ΙΙΙβ lung cancer patients with high or low serum Ang-2 at baseline. (B) Overall survival for stage IV lung cancer patients with high or low serum Ang-2 at baseline.

• 

  Figure 3. Kaplan–Meier curve for overall survival grouped by baseline serum Ang-2 levels. (A) Overall survival for stage ΙΙΙβ NSCLC patients with high or low serum Ang-2 at baseline. (B) Overall survival for stage IV NSCLC patients with high or low serum Ang-2 at baseline.

• 

  Figure 4. Kaplan–Meier curve for overall survival grouped by baseline serum Ang-2 levels. (A) Overall survival for stage ΙΙΙβ SCLC patients with high or low serum Ang-2 at baseline. (B) Overall survival for stage IV SCLC patients with high or low serum Ang-2 at baseline.

• 

  Figure 5. Ang-2 serum levels of patients at the third cycle of chemotherapy. (A) Ang-2 serum levels of NSCLC patients who received PBC in combination with anti-VEGF before treatment and after the third cycle of chemotherapy. (B) Ang-2 serum levels of SCLC patients who received PBC before treatment and after the third cycle of chemotherapy.